Related Experiment Video
Updated: Aug 29, 2026
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Vasoactive drugs and the kidney
Raymond Wai Chuen Lee1, David Di Giantomasso, Clive May
1Florey Research Institute, Melbourne, Australia.
Abstract:
Protection of renal function and prevention of acute renal failure (ARF) are important goals of resuscitation in critically ill patients. Beyond fluid resuscitation and avoidance of nephrotoxins, little is known about how such prevention can be achieved. Vasoactive drugs are often administered to improve either cardiac output or mean arterial pressure in the hope that renal blood flow will also be improved and, thereby, renal protection achieved. Some of these drugs (especially low-dose dopamine) have even been proposed to have a specific beneficial effect on renal blood flow. However, when all studies dealing with vasoactive drugs and their effects on the kidney are reviewed, it is clear that none have been demonstrated to achieve clinically important benefits in terms of renal protection. It is also clear that, with the exception of low-dose dopamine, there have been no randomized controlled trials of sufficient statistical power to detect differences in clinically meaningful outcomes. In the absence of such data, all that is available is based on limited physiological gains (changes in renal blood flow or urine output) with one or another drug in one or another subpopulation of patients. Furthermore, given our lack of understanding of the pathogenesis of ARF, it is unclear whether haemodynamic manipulation is an appropriate avenue to achieve renal protection. There is a great need for large randomized controlled trials to test the clinical, instead of physiological, effects of vasoactive drugs in critical illness.
Insights
Protecting kidney function in critically ill patients is crucial. Current evidence shows vasoactive drugs offer no proven clinical benefit for preventing acute renal failure (ARF), highlighting a need for more research.
Area of Science:
- Critical Care Medicine
- Nephrology
- Pharmacology
Background:
- Protecting renal function and preventing acute renal failure (ARF) are key goals in critical care resuscitation.
- Current strategies beyond fluids and avoiding nephrotoxins are limited.
- Vasoactive drugs are frequently used to improve hemodynamics, with hopes of enhancing renal blood flow and function.
Purpose of the Study:
- To review the evidence on vasoactive drugs for renal protection in critically ill patients.
- To assess the clinical benefits of vasoactive drugs in preventing acute renal failure.
- To identify the need for further research in this area.
Main Methods:
- Comprehensive review of studies on vasoactive drugs and their effects on the kidney.
- Analysis of available data regarding renal blood flow and urine output.
- Evaluation of the statistical power of existing randomized controlled trials.
Main Results:
- No vasoactive drug has demonstrated clinically significant benefits for renal protection.
- Except for low-dose dopamine, few randomized controlled trials have sufficient power to detect meaningful clinical outcomes.
- Observed physiological gains (renal blood flow, urine output) are limited and lack clear clinical relevance.
Conclusions:
- Current evidence does not support the use of vasoactive drugs for clinically important renal protection in critical illness.
- The efficacy of hemodynamic manipulation for preventing ARF remains uncertain due to a lack of understanding of its pathogenesis.
- Large randomized controlled trials are essential to evaluate the clinical effects of vasoactive drugs on patient outcomes, not just physiological parameters.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
01:16Antihypertensive Drugs: Action of Diuretics
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics